FATTY LIVER DISEASE IN SOCIAL REINTEGRATION FACILITIES CLIENTS
DOI:
https://doi.org/10.32782/2077-6594.3.1.2021.240803Keywords:
NAFLD – Non-alcoholic fatty liver disease, liver diseases, social reintegration facilityAbstract
NAFLD (Non-alcoholic fatty liver disease) is characterized by the presence of hepatic steatosis, i. e. excessive accumulation of fat in liver tissue that is associated with insulin resistance. NAFLD/NASH is considered to be an organ/liver manifestation of the metabolic syndrome, and is likely to play a key role in the pathogenesis of systemic atherosclerosis. The project "Screening of liver diseases in social reintegration facility" ran from 1/2020 to 10/2020. It was carried out within the institutional project of the St. Elizabeth University of Health and Social Sciences (VŠZaSP sv. Alžbety) and the Slovak Society of Practical Obesitology (SSPO) at the Institute of Christ the High Priest in Žakovce.
The aim of the research was: a) to find a correlation between the degree of fibrosis and the degree of CAP; b) to determine the correlation between NH3 and fat spectrum indicators (CHOL, TAG, LDL, HDL); c) to determine the correlation between the NH3 level and the CAP level. The author evaluates individual results of the projects in the article. Besides taking care of our outpatient clinics patients, we should not forget about clients of the social reintegration facilities, in whom due to the presence of several risk factors, the incidence of liver diseases and other diseases of civilization is even higher compared to the general population.
References
Holomáň, J., Szántová, M., Zima, M., Slobodová, Ľ. Management of non – alcoholic fatty liver disease. Via pract., 2016, 13(5): 179 -186. ISSN 1339-424X (Online).
Vernon, G., Baranova, A., Younossi, ZM.. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ter. 2011; 34: 274-285.ISSN:1365-2036 (Online).
Leite, NC., Villea-Nogueria, CA., Cardoso, CRL., Salles, GF. Non-alcoholic fatty liver disease and diabetes. From pathophysiological interplay to diagnosis and treatment. WJG. 2014; 14: 8377/8392. ISSN 2219-2840 (online).
Dražilová, S. Non-alcoholic fatty liver disease. p. 249.265. In: Dražilová, S., Gombošová, L., Janíčko, M., Skladaný, Ľ., Veselíny, E. Selected chapters from hepatology gastroenterology. Košice: UPJŠ LF, 2020, 284 p. ISBN 978-80-8152-838-5 (e-publication)
EASL-EAS-EASO Clinical Practice Guidelines: For the management of Non-Alcoholic Fatty Liver Disease. J Hep.2016; http://dx.doi.org/10.2016/j.jhep. 2015.11.004.
Belovičová, M. Selected liver diseases and their impact on public health. Bardejov: SSPO, 2018, p. 159. ISBN 978-80-971460-6-1.
Belovičová, M. Non-alcoholic fatty liver disease and its impact on public health. Krakow: Towarzystwo Slowakow w Polsce, 2019, p. 96. ISBN 978-83-8111-142-3.
Holomáň, J., Szántová, M., Zima, M., Koller, T., Fábryová, Ľ. Non-alcoholic fatty liver disease – standard diagnostic and therapeutic procedure. 63. Methodical sheet of rational pharmacotherapy.2017; 20 (1-2).
Belovičová, M., Mašterová, V. Non-alcoholic fatty liver disease – severe comorbidity of diabetes. Forum Diab 2016; 5(1): 45-48. ISSN 1805–3807.
Špičák, J. Covid-19 a hepatogastroenterologie. Gastroent Hepatol 2020; 74(5): 415-423. ISSN 1804-7874.
